Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow

By LabMedica International staff writers
Posted on 18 Feb 2026

Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. More...

Yet consistent, repeatable bacillary assessment across programs can be difficult, and variability in slide reading affects workflow efficiency. A new system has launched that digitizes and standardizes smear workflows with artificial intelligence to automate acid‑fast bacilli detection and objective bacillary grading.

OptraSCAN has introduced BactoSiA, an artificial intelligence-assisted tuberculosis treatment monitoring and follow‑up solution built to support sputum smear microscopy. The system is designed to deliver slide‑to‑report results in minutes and generate standardized bacillary load grades (Scanty, 1+, 2+, 3+) aligned with internationally recognized tuberculosis reporting guidelines. It targets consistent interpretation to support downstream decision‑making within existing laboratory operations.

BactoSiA combines high‑resolution brightfield whole‑slide imaging with AI-based algorithms to automatically detect and quantify acid‑fast bacilli (AFB) on Ziehl–Neelsen-stained sputum samples. Powered by OptraSCAN’s patented OS‑SiA technology, the platform performs scanning, indexing, and AI‑driven analysis simultaneously. During acquisition, likely positive regions are flagged to support slide triage, confirmed positives are graded automatically using standardized criteria, and images and reports are managed within the IMAGEPath software ecosystem.

The system is optimized for public health laboratories, mid‑ and high‑volume tuberculosis laboratories, mobile units, nongovernmental organizations, and telepathology networks where repeat testing and treatment monitoring are routine. It is designed to reduce reader variability, improve throughput, and maintain operational efficiency across diverse and decentralized settings with digital reporting and minimal infrastructure and training requirements. The approach addresses the need for speed, standardization, and scalability in smear microscopy workflows.

OptraSCAN introduced BactoSiA at WHX Labs World Health Expo in Dubai 2026, where the company conducted live, hands-on demonstrations at its booth. As part of the event’s Clinical Microbiology Track, Devika Gholap, Chief Product Officer at OptraSCAN, delivered a technology and innovation spotlight presentation titled “Implementation Science Considerations for Digitally Enabled Tuberculosis Microscopy”. The session examined practical considerations for scaling digital and AI-enabled TB microscopy, drawing on real-world laboratory and screening program experience.

“Tuberculosis care cascade depends on how well different tools work together within real‑world health systems,” said Devika Gholap, Chief Product Officer at OptraSCAN. “By bringing automation and standardized bacillary grading to one of the most widely used TB tests in the world, BactoSiA helps laboratories reduce reader variability, improve throughput, and deliver more consistent results, without adding operational complexity. This approach supports real‑world implementation at scale.”

Related Links
OptraSCAN


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.